Spongipyran Synthetic Studies. Evolution of a Scalable Total Synthesis of (+)-Spongistatin 1 - PubMed (original) (raw)
. 2009 Sep 15;65(33):6489-6509.
doi: 10.1016/j.tet.2009.04.003.
Chris Sfouggatakis, Christina A Risatti, Jeffrey B Sperry, Wenyu Zhu, Victoria A Doughty, Takashi Tomioka, Dimitar B Gotchev, Clay S Bennett, Satoshi Sakamoto, Onur Atasoylu, Shohei Shirakami, David Bauer, Makoto Takeuchi, Jyunichi Koyanagi, Yasuharu Sakamoto
Affiliations
- PMID: 20640040
- PMCID: PMC2902791
- DOI: 10.1016/j.tet.2009.04.003
Spongipyran Synthetic Studies. Evolution of a Scalable Total Synthesis of (+)-Spongistatin 1
Amos B Smith et al. Tetrahedron. 2009.
Abstract
Three syntheses of the architecturally complex, cytotoxic marine macrolide (+)-spongistatin 1 (1) are reported. Highlights of the first-generation synthesis include: use of a dithiane multicomponent linchpin coupling tactic for construction of the AB and CD spiroketals, and their union via a highly selective Evans boron-mediated aldol reaction en route to an ABCD aldehyde; introduction of the C(44)-C(51) side chain via a Lewis acid-mediated ring opening of a glucal epoxide with an allylstannane to assemble the EF subunit; and final fragment union via Wittig coupling of the ABCD and EF subunits to form the C(28)-C(29) olefin, followed by regioselective Yamaguchi macrolactonization and global deprotection. The second- and third- generation syntheses, designed with the goal of accessing one gram of (+)-spongistatin 1 (1), maintain both the first-generation strategy for the ABCD aldehyde and final fragment union, while incorporating two more efficient approaches for construction of the EF Wittig salt. The latter combine the original chelation-controlled dithiane union of the E- and F-ring progenitors with application of a highly efficient cyanohydrin alkylation to append the F-ring side chain, in conjunction with two independent tactics to access the F-ring pyran. The first F-ring synthesis showcases a Petasis-Ferrier union/rearrangement protocol to access tetrahydropyrans, permitting the preparation of 750 mgs of the EF Wittig salt, which in turn was converted to 80 mg of (+)-spongistatin 1, while the second F-ring strategy, incorporates an organocatalytic aldol reaction as the key construct, permitting completion of 1.009 g of totally synthetic (+)-spongistatin 1 (1). A brief analysis of the three syntheses alongside our earlier synthesis of (+)-spongistatin 2 is also presented.
Figures
Similar articles
- Spongipyran Synthetic Studies. Total Synthesis of (+)-Spongistatin 2.
Smith AB, Lin Q, Doughty VA, Zhuang L, McBriar MD, Kerns JK, Boldi AM, Murase N, Moser WH, Brook CS, Bennett CS, Nakayama K, Sobukawa M, Lee Trout RE. Smith AB, et al. Tetrahedron. 2009 Aug 15;65(33):6470-6488. doi: 10.1016/j.tet.2009.04.001. Tetrahedron. 2009. PMID: 20161196 Free PMC article. - Gram-scale synthesis of (+)-spongistatin 1: development of an improved, scalable synthesis of the F-ring subunit, fragment union, and final elaboration.
Smith AB 3rd, Tomioka T, Risatti CA, Sperry JB, Sfouggatakis C. Smith AB 3rd, et al. Org Lett. 2008 Oct 2;10(19):4359-62. doi: 10.1021/ol801792k. Epub 2008 Aug 28. Org Lett. 2008. PMID: 18754594 Free PMC article. - Spongistatin synthetic studies. evolution of a scalable synthesis for the EF fragment of (+)-Spongistatin 1 exploiting a Petasis-Ferrier union/rearrangement tactic.
Smith AB 3rd, Sfouggatakis C, Gotchev DB, Shirakami S, Bauer D, Zhu W, Doughty VA. Smith AB 3rd, et al. Org Lett. 2004 Sep 30;6(20):3637-40. doi: 10.1021/ol048418f. Org Lett. 2004. PMID: 15387567 - [Stereoselective synthesis of macrolide and polyether antibiotics].
Yonemitsu O. Yonemitsu O. Yakugaku Zasshi. 1990 Aug;110(8):523-46. doi: 10.1248/yakushi1947.110.8_523. Yakugaku Zasshi. 1990. PMID: 2273449 Review. Japanese. - Evolution of Anion Relay Chemistry: Construction of Architecturally Complex Natural Products.
Deng Y, Smith AB 3rd. Deng Y, et al. Acc Chem Res. 2020 Apr 21;53(4):988-1000. doi: 10.1021/acs.accounts.0c00076. Epub 2020 Apr 9. Acc Chem Res. 2020. PMID: 32270672 Free PMC article. Review.
Cited by
- Marine Invertebrate Metabolites with Anticancer Activities: Solutions to the "Supply Problem".
Gomes NG, Dasari R, Chandra S, Kiss R, Kornienko A. Gomes NG, et al. Mar Drugs. 2016 May 21;14(5):98. doi: 10.3390/md14050098. Mar Drugs. 2016. PMID: 27213412 Free PMC article. Review. - Design, synthesis, and biological evaluation of diminutive forms of (+)-spongistatin 1: lessons learned.
Smith AB 3rd, Risatti CA, Atasoylu O, Bennett CS, Liu J, Cheng H, TenDyke K, Xu Q. Smith AB 3rd, et al. J Am Chem Soc. 2011 Sep 7;133(35):14042-53. doi: 10.1021/ja2046167. Epub 2011 Aug 12. J Am Chem Soc. 2011. PMID: 21761891 Free PMC article. - Diversity-oriented synthesis leads to an effective class of bifunctional linchpins uniting anion relay chemistry (ARC) with benzyne reactivity.
Smith AB 3rd, Kim WS. Smith AB 3rd, et al. Proc Natl Acad Sci U S A. 2011 Apr 26;108(17):6787-92. doi: 10.1073/pnas.1015265108. Epub 2011 Jan 18. Proc Natl Acad Sci U S A. 2011. PMID: 21245309 Free PMC article. - A reductive coupling strategy towards ripostatin A.
Schleicher KD, Jamison TF. Schleicher KD, et al. Beilstein J Org Chem. 2013 Jul 31;9:1533-50. doi: 10.3762/bjoc.9.175. eCollection 2013. Beilstein J Org Chem. 2013. PMID: 23946853 Free PMC article. - Design and 22-step synthesis of highly potent D-ring modified and linker-equipped analogs of spongistatin 1.
Suen LM, Tekle-Smith MA, Williamson KS, Infantine JR, Reznik SK, Tanis PS, Casselman TD, Sackett DL, Leighton JL. Suen LM, et al. Nat Commun. 2018 Nov 9;9(1):4710. doi: 10.1038/s41467-018-07259-x. Nat Commun. 2018. PMID: 30413713 Free PMC article.
References
- Pettit GR, Cichacz ZA, Gao F, Herald CL, Boyd MR, Schmidt JM, Hooper JNA. J Org Chem. 1993;58:1302.
- Kobayashi M, Aoki S, Sakai H, Kawazoe K, Kihara N, Sasaki T, Kitagawa I. Tetrahedron Lett. 1993;34:2795.
- Fusetani N, Shinoda K, Matsunaga S. J Am Chem Soc. 1993;115:3977.
- Pettit noted that 400 kg of wet sponge yielded only 13.8 mg of (+)-spongistatin 1. see: Pettit GR, Cichacz ZA, Gao F, Herald CL, Boyd MR, Schmidt JM, Hooper JNA. J Org Chem. 1993;58:1302.
- Evans DA, Coleman PJ, Dias LC. Angew Chem, Int Ed. 1997;36:2738.
- Evans DA, Trotter BW, Côté B, Coleman PJ. Angew Chem, Int Ed. 1997;36:2741.
- Evans DA, Trotter BW, Côté B, Coleman PJ, Dias LC, Tyler AN. Angew Chem, Int Ed. 1997;36:2744.
- Evans DA, Trotter BW, Coleman PJ, Côté B, Dias LC, Rajapakse HA, Tyler AN. Tetrahedron. 1999;55:8671.
- Guo J, Duffy KJ, Stevens KL, Dalko PI, Roth RM, Hayward MM, Kishi Y. Angew Chem, Int Ed. 1998;37:187.
- Hayward MM, Roth RM, Duffy KJ, Dalko PI, Stevens KL, Guo J, Kishi Y. Angew Chem, Int Ed. 1998;37:190.
- Smith AB, III, Doughty VA, Lin Q, Zhuang L, McBriar MD, Boldi AM, Moser WH, Murase N, Nakayama K, Sobukawa M. Angew Chem, Int Ed. 2001;40:191. - PubMed
- Smith AB, III, Lin Q, Doughty VA, Zhuang L, McBriar MD, Kerns JK, Brook CS, Murase N, Nakayama K. Angew Chem, Int Ed. 2001;40:196. - PubMed
- Smith AB, III, Zhu W, Shirakami S, Sfouggatakis C, Doughty VA, Bennett CS, Sakamoto Y. Org Lett. 2003;5:761. - PubMed
- Smith AB, III, Tomioka T, Risatti CA, Sperry JB, Sfouggatakis C. Org Lett. 2008;19:4359. - PMC - PubMed
- Paterson I, Chen DYK, Coster MJ, Acenã JL, Bach J, Gibson KR, Keown LE, Oballa RM, Trieselmann T, Wallace DJ, Hodgson AP, Norcross RD. Angew Chem, Int Ed. 2001;40:4055. - PubMed
- Crimmins MT, Katz JD, Washburn DG, Allwein SP, McAtee LF. J Am Chem Soc. 2002;124:5661. - PubMed
- Hubbs JL, Heathcock CH. J Am Chem Soc. 2003;125:12836. - PubMed
- Heathcock CH, McLaughlin M, Medina J, Hubbs JL, Wallace GA, Scott R, Claffey MM, Hayes CJ, Ott GR. J Am Chem Soc. 2003;125:12844. - PubMed
- Ball M, Gaunt MJ, Hook DF, Jessiman AS, Kawahara S, Orsini P, Scolaro A, Talbot AC, Tanner HR, Yamanoi S, Ley SV. Angew Chem, Int Ed. 2005;44:5433. - PubMed
- Smith AB, III, Doughty VA, Sfouggatakis C, Bennett CS, Koyanagi J, Takeuchi M. Org Lett. 2002;4:783. - PubMed
- Paterson I, Wallace DJ, Oballa RM. Tetrahedron Lett. 1998;39:8545.
- Paterson I, Chen DYK, Coster MJ, Acena JL, Bach J, Wallace DJ. Org Biomol Chem. 2005;3:2431. - PubMed
- Smith AB, III, Lin Q, Doughty VA, Bennett CS, Zhuang L, McBriar MD, Kerns JK, Boldi AM, Murase N, Moser WH, Brook CS, Nakayama K, Sobukawa M, Trout REL. manuscript submitted.
Grants and funding
- R01 CA070329-04/CA/NCI NIH HHS/United States
- R01 CA070329-03/CA/NCI NIH HHS/United States
- R01 CA070329-09/CA/NCI NIH HHS/United States
- R01 CA070329/CA/NCI NIH HHS/United States
- R01 CA070329-11/CA/NCI NIH HHS/United States
- R01 CA070329-10/CA/NCI NIH HHS/United States
- R01 CA070329-06/CA/NCI NIH HHS/United States
- F32 CA121716/CA/NCI NIH HHS/United States
- R01 CA070329-08/CA/NCI NIH HHS/United States
- R01 CA070329-05/CA/NCI NIH HHS/United States
- R01 CA070329-07/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Research Materials